Progress of molecular targeted therapy in acute myeloid leukemia
Acute myeloid leukemia(AML)is a highly heterogeneous hematologic malignancy.The conven-tional treatment of AML is cytotoxic chemotherapy.However,the overall survival of AML is not ideal and the 5-year survival rate is less than 30％.Recently,a series of novel molecular targeted drugs have been developed.These drugs have significantly improved the prognosis of patients with AML and provided more treatment op-tions.This article reviews the progress of molecular targeted therapy in AML.
NETL
NSTL
万方数据
